Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib plus intensive chemotherapy in newly diagnosed FLT3-ITD-positive AML
jRCTs041250036Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: 1-year relapse-free survival rate in patients who achieved complete remission (CR). Started May 2025; status: recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCTs041250036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250036.